InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,222.80
(
0.08%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.62
(
0.71%
)
Bitcoin
62,808.57
(
-0.55%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 83
Posts 12467
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: JJM760 post# 2822

Monday, 10/25/2010 7:04:21 PM

Monday, October 25, 2010 7:04:21 PM

Post# of 80490
Harvey might be a mad man based on this statement today:

"Importantly, the Company anticipates that this funding will allow ARIAD to retain the substantial potential commercial value of ponatinib in multiple lines of treatment for chronic myeloid leukemia (CML) and other cancers by focusing its partnering strategy on a regional collaboration in select markets outside of the U.S. The Company does not intend to pursue a global partnership for ponatinib."

He hasn't learned his lesson. This is the stratagy he followed with Ridaforolimus. He will HAVE to do ANOTHER secondary in early 2012 to survive..
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up